Open Access: This is an open access article distributed under the terms of the CC-BY License. Individuals aged 60 to 69 years were more likely to report systemic AEs than were individuals 70 years or older (20.5% vs 13.6%).Īccepted for Publication: February 24, 2022.
The proportion of females who reported systemic reactions was nearly double that of males (22.9% vs 11.4%). Only 1.2% sought medical attention owing to an AE.įemales were more likely than males to report AEs (39.0% vs 22.6%). Most of the respondents (67.8%) reported that their general feeling after the booster was similar to the feeling after the second dose 18.7% and 11.1% reported a milder or worse response, respectively. The most common AEs included pain at the injection site (23.5%), fatigue (9.7%), and malaise (7.2%) ( Table 2). Of the respondents, 30.0% reported at least 1 AE, 24.8% reported local reactions, and 16.6% reported systemic reactions. The proportion of female respondents was 45.3%, and 49.2% had at least 1 risk factor for severe COVID-19 ( Table 1). The median age of respondents was 71 years (IQR, 66-75 years) 43.6% of respondents were aged 60 to 69 years 44.5%, 70 to 79 years and 12.0%, 80 years or older. Of 82 392 CHS members 60 years or older who received a booster dose during the study period, 66 094 were contacted, with 27 046 (40.9%) responding to the survey. Individuals’ demographic and clinical characteristics were extracted from their electronic health records.
For participants who responded to both surveys, we considered only the latter response. The survey process comprised 2 sequential surveys conducted 5 to 11 days (August 8-10, 2021) and 20 to 28 days (August 23-26, 2021) after the initiation of the campaign. For those 80 years or older, a random sample (41.8%) was contacted by telephone and interviewed. Individuals aged 60 to 79 years were sent a text message with a request to complete an online survey (eTable in the Supplement) regarding AEs. This study followed the AAPOR reporting guideline for survey studies. The CHS institutional review board approved this study, with a waiver of informed consent because deidentified survey data were used. Study participants were individuals 60 years or older who received the booster dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in the first 5 days of the campaign (July 30 to August 3, 2021). This study was conducted among members of Clalit Health Services (CHS), which insures more than half of the Israeli population. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
0 kommentar(er)
